Managing residual risk in patients receiving statin therapy.
Until the results of several statin trials are available, it is recommended that the current indications and usage of ezetimibe be continued.
Hamilton-Craig
Ian R
IR
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors